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The structural requirements for inhibition of bacterial RNA polymerase and rabbit liver formyltetrahydrofolate 
synthetase activity by a series of purine nucleoside analogs related to 6chloro-8-aza-9cyclopentylpurine (689) were 
investigated. To achieve an inhibitory effect, preincubation of the enzyme preparations with the purine analogs, 
prior to assay of enzyme activity, was required. The greatest inhibition was produced by analogs containing all three 
alterations of the purine nucleoside structure: the 6-halo, 8-aza, and 9cyclopentyl groups. It is suggested that 689 
inhibits the activity of enzymes involved in nucleic acid synthesis by a site-directed alkylation. 
1. Introduction 
The purine nucleoside analog 6chloro-8-aza-9- 
cyclopentylpurine (689) has been shown to inhibit the 
synthesis of DNA, RNA, and protein independently in 
Escherichiu coli [ 1,2]. Further studies revealed that 
although thymine nucleotide formation in vivo was 
markedly inhibited, thymidylate synthetase activity 
measured in vitro was unaffected by 689 [2]. 
Enzyme inhibition by 689 is a rather selective ac- 
tion. As reported previously [2], only certain enzymes 
concerned with polynucleotide formation or metabs 
lism appear to be affected by 689. Because of this se- 
lective effect, it was considered pertinent to determine 
the structural characteristics of the purine nucleoside 
analogs required to produce enzyme inhibition and 
whether the structure-activity relationships for inhi- 
bition of different drug-affected enzymes were similar. 
RNA polymerase, which was shown to be sensitive to 
inhibition by 689 [2] , was studied along with formyl- 
tetrahydrofolate synthetase to explore further the 
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structural requirements necessary for inhibition of en- 
zyme activity. The inhibition of RNA polymerase ac- 
tivity takes on special significance because of the fact 
that there are few known inhibitors of this enzyme 
which act by interfering with the enzyme directly, 
rather than the template. 
2. Materials and methods 
2.1. Compounds 
The synthesis of 689 and 6-substituted-8-aza-9- 
cyclopentylpurine analogs has been reported [3]. The 
other analogs were generously contributed by either 
Drs. P.K.Chang and A.C.Sartorelli of the Department 
of Pharmacology, Yale University, New Haven, Conn.; 
Dr. J.A.Montgomery, Southern Research Institute, 
Birmingham, Alabama; Dr. R.K.Robins of the Depart- 
ment of Chemistry, University of Utah, Salt Lake, City, 
Utah; or Dr. H.J.Schaeffer, State University of New 
York, Buffalo. dl,L-tetrahydrofolic acid and 6-chloro- 
purine riboside were purchased from the Sigma Che- 
mical Co., adenine from Calbiochem, and 14C-ATP 
(410 mCi/mmole) from New England Nuclear Corp. 
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2.2. Enzymes 
RNA polymerase (nucleosidetriphosphate: RNA 
nucleotidyltransferase, E.C. 2.7.7.6), partially purified 
from E. coli or Micrococcus Zysodeikticus, was obtained 
from Miles Laboratories. The enzyme preparations had 
a specific activity of 250-500 units/mg protein (a unit 
being that activity catalyzing the incorporation of 1 
nmole of ATP into RNA in 10 min at 37” and pH 7.9 
with calf thymus DNA as template). Formyltetrahy- 
drofolate synthetase (formate: tetrahydrofolate ligase 
(ADP), E.C. 6.3.4.3) was prepared from rabbit liver 
by homogenizing the liver in a precooled blendor in 5 
volumes of buffer (0.5 M tris-HCl-0.05 M EDTA di- 
sodium, pH 7.2). Solid ammonium sulfate was added 
to the homogenate slowly with stirring at 0” until 50% 
saturation was reached. The precipitate was discarded, 
and additional ammonium sulfate was added to the 
supernatant fraction to attain 70% saturation. The 
precipitate was collected by centrifugation and redis- 
solved in tris-EDTA buffer (as above), divided into 
aliquots, and frozen. The enzyme fraction had a spe- 
cific activity of 10 units/mg protein (I unit is defined 
as a change in absorbance of 1 absorbance unit at 355 
nm in 10 min) and was diluted with tris-EDTA prior 
to use. Formyltetrahydrofolate synthetase was also 
extracted and partially purified [5] from lyophilized 
Clostridium cylindrosporum obtained from Worthing- 
ton Biochemical Corp. The final fraction had a specific 
activity of 5400 units/mg protein. 
2.3. Assay ofRNA polymerase activity 
The enzyme preparation (25-50 r_lg protein) was 
preincubated at 37” for 60 min with gentle shaking, 
in a 0.26 ml reaction mixture containing 12.5% di- 
methylsulfoxide (necessary to dissolve the purine 
analogs), 20 mM tris-HCl (pH 7.5), 5 mM MgC12, 50 
mM KCI, 2.5 mM /3-mercaptoethanol, and 25 pg of 
bovine serum albumin. The purine analogs were added 
in a concentration of 2 mM to the preincubation mix- 
tures, and control samples were incubated under the 
same conditions but in the absence of drugs. RNA 
polymerase activity was assayed in a 0.4 ml reaction 
mixture containing 24 pmoles trisHC1, pH 8.0; 4.5 
pmoles MgC12; 0.85 pmole fl-mercaptoethanol; 100 
nmoles each of CTP, GTP, UTP; 10 nmoles 14C-ATP 
(0.5 PCi); 30 pg calf thymus DNA (Worthington); 
and lo-25 units of preincubated polymerase. After 
incubation at 37” for 30 min, reactions were stopped 
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by the addition of 3 ml of cold 5% trichloroacetic 
acid, filtered on Millipore filters (0.45 pm pore size), 
washed three times with cold 2.5% TCA, placed in 
counting vials, dried, and counted in 10 ml of toluene 
scintillator on a Packard TriCarb liquid scintillation 
spectrometer. All assays of enzyme activity were de- 
termined in duplicate samples. 
2.4. Assay of formyltetrahydrofolate synthetase acti- 
vity 
The incubation mixture consisted of the following 
components: 50 mM trisHC1 (pH 7.5), 20 mM 
MgC12.6 H20,50 mM NH&I, 5 mM ATP, 10 mM as- 
corbic acid, 1.2 mM tetrahydrofolic acid, 50 mM so- 
dium formate, and enzyme in a total volume of 3 ml. 
A reaction mixture which included the potential in- 
hibitor, but without sodium formate, was utilized as a 
blank for each compound tested. Unless otherwise 
specified, the enzymic extract was initially preincubated 
with the potential inhibitors in a total volume of 0.2 
ml for 3 min at 37”, after which the remainder of the 
reaction components were added, and the entire mix- 
ture was incubated for 20 min. The reaction was ter- 
minated by the addition of 0.2 ml of 70% perchloric 
acid; the N1o-formyltetrahydrofolate formed during 
the reaction was thereby converted to fl, NrOmethe- 
nyltetrahydrofolate. The mixture was cooled, centri- 
fuged, and the absorbancy of the supernatant due to 
the formation of I@, Nl”-methenyltetrahydrofolate 
was determined at 355 nm. All of the compounds 
tested were dissolved in dimethyl sulfoxide (DMSO) 
prior to use; comparable concentrations of DMSO 
were added to nondrug-treated extracts to serve as 
controls. 
3. Results 
Table 1 indicates the effect of 689 and various re- 
lated purine nucleoside analogs on RNA polymerase 
activity. A concentration of 2 mM 689 produced virt- 
ually a complete loss of polymerase activity when the 
enzyme was preincubated for 60 min with drug (0.2 
mM 689 produced a 25% decrease in activity), and 
the inhibition was essentially irreversible. No inhibi- 
tion of RNA polymerase function was observed when 
purified calf thymus DNA was pretreated with 689 
prior to utilizing the DNA as a template for the RNA 
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Table 1 
Inhibition of RNA polymerase activity by 689 and related analogs. RNA polymerase from E. coli (Experiment 1) or M. lysodeiktus 
(Experiments 2 and 3) was preincubated for 60 min in buffer alone (control) or with 2 mM of the various purine analogs, and ac- 
tivity was assayed as described in Materials and methods. The lower incorporations of labeled precursor in Experiment 3 reflect a 
decrease in enzyme activity with storage of the enzyme preparation. 
Agent 
Experiment 1 
14C-ATP Decrease 
incorporated/mg DNA from control 
@moles) (%I 
Control 
6Chloro-8-aza-9cyclopentylpurine (689) 
6-Bromo-8-aza-9-cyclopentylpurine 
6-lodo-8-aza-9-cyclopentylpurine 
6-Mercapto-8-aza-9-cyclopentylpurine 
8-Aza-9-cyclopentylpurine 
6Chloro-8-azapurine 
6Chloropurine riboside 
6Chloropurine deoxyriboside 
6Chloropurine 
Experiment 2 
23.6 
2.2 91 
1.2 95 
4.2 82 
17.4 26 
26.9 - 
22.5 
22.2 
24.5 
26.4 
Control 
689 
6-Amino-2-aza-9cyclopentylpurine 
Experiment 3 
34.8 
22.3 36 
36.7 
Control 7.8 
689 4.9 37 
6Chloro-9-cyclopentylpurine 8.2 - 
6-Hydroxy-8-aza-9-cyclopentylpurine 8.1 - 
synthesis reaction. Thus a concentration of 2 mM for sent, essentially no inhibitory activity was observed. 
each analog and a preincubation time of 60 min was The analogs lacking the 6-halo group or the cyclo- 
used as a screening procedure to determine the relative pentyl group were inactive, as were 6chloropurine, 
activities of each agent as an RNA polymerase inhibitor. its riboside, and deoxyriboside. 
It can be seen from table 1 that 689 produced 91% 
inhibition of E. coli RNA polymerase. The 6-bromo 
derivative was slightly more active, and the 6-iodo was 
somewhat less effective than 689. The 6-mercapto 
analog had only slight activity. If one of the three 
deviations of the purine nucleoside structure were ab 
The data presented in Experiments 2 and 3 (table 
1) were obtained using RNA polymerase from M. lyso- 
deikticus. It is interesting that the enzyme from this 
source was much less sensitive to 689 than that derived 
from E. coli. The results of these experiments give 
further support to the concept that the basic alteration 
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Table 2 
Effect of purine analogs upon formyltetrahydrofolate synthetase activity* 
Compound Concentration** 
(mM) 
Decrease 
from control 
(%) 
6Chloro-8-aza-9-cyclopentylpurine (689) 
6Choropurine 
6Chloro-9-cyclopentylpurine 
6-Hydroxy-8-aza-9-cyclopentylpurine 
6-Mercapto-8-aza-9cyclopentylpurine 
6-Amino-8-aza-9cyclopentylpurine 
Adenine 
9Cyclopentyladenine 
0.3 17 
0.75 50 
1.5 80 
3.0 86 
3.0 
30.0 
3.0 
30.0 
3.0 
30.0 
3.0 
7.5 
7.5*** 
3.0 
3.0 
0 
10 
0 
25 
0 
19 
13 
35 
5 
0 
0 
* Compounds were preincubated with the enzyme fraction at 37O for 3 min, after which the reaction components were added 
and the entire mixture was incubated for another 20 min. 
** The concentration of inhibitor preincubated irectly with the enzyme. 
*** This compound was not soluble at the concentration indicated, and the reaction mixture was cloudy. 
of the purine nucleus present in 689 are required for 
inhibition of polymerase activity. The agents lacking 
a halogen in position 6 or the 8-aza group were inef- 
fective. 
The results in table 2 indicate that the inhibition of 
formyltetrahydrofolate synthetase activity from rabbit 
liver was dependent upon the concentration of 689. 
The data in fig. 1 show that enzyme activity decreased 
with an increase in the duration of preincubation; thus, 
when a concentration of 0.68 mM 689 was preincu- 
bated with the enzymic fraction for 32 min, activity 
was reduced to 10% of the control value. Preincubation 
of the enzyme without 689 did not result in a loss of 
activity. 
To determine the structural requirements for inhi- 
bition of formyltetrahydrofolate synthetase, several 
structurally related compounds were tested as inhi- 
bitors of this enzyme. The data in table 2 indicate that 
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689 inhibited formyltetrahydrofolate synthetase ac- 
tivity more effectively than did the other purine ana- 
logs examined. The other 6chlorocontaining analogs 
(6-chloropurine and 6chloro9-cyclopentylpurine) as 
well as several compounds possessing the 8-aza-9- 
cyclopentyl substitutions, such as 6-hydroxy-8-aza-9- 
cyclopentylpurine, 6-mercapto-8-aza-9-cyclopentyl- 
purine, and 6-amino-8-aza-9cyclopentylpurine, inhi- 
bited enzyme activity to a much lesser degree. The 
free base adenine and 9-cyclopentyladenine were not 
active at a concentration of 3.0 mM. 
Experiments were carried out to test whether any 
of the three substrates, ATP, formate, or tetrahydro- 
folate, could protect the enzyme from inhibition by 
689. Preincubation of either ATP, formate, or tetra- 
hydrofolate with 689 or with enzyme prior to the ad- 
dition of 689 did not protect the enzyme. In contrast, 
preincubation of the enzyme with magnesium ions 
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TIME OF PREINCUEATION lmin) 
Fig. 1. The effect of the duration of preincubation with 0.68 
mM 689 upon formyltetrahydrofolate synthetase from rabbit 
liver. After the desired time of preincubation, the reaction 
components (see Materials and methods) were added, and the 
total mixture was incubated for another 20 min. 
(MgC12.6 H20, 12.3 mM) or with other cations (chlo- 
ride salts of Mn2+, Ni2+, Cd’, Ca2+, Fe3+, Sn2+) prior 
to the addition of 689 resulted in less inhibition of 
enzyme activity. However, preincubation of the en- 
zyme preparation with 689 prior to the addition of the 
cation resulted in an inhibition of activity similar to 
that observed in the absence of additional cation. The 
protective effect of the cations was studied using several 
concentrations of both inhibitor and magnesium chlor- 
ide. The data in fig. 2 indicate that the protective effect 
of Mg2’ was dose dependent. Since it was possible 
that Mg2’ interacted with 689 and thereby prevented 
its effects upon the enzymes, 689 was incubated alone 
or with Mg2’ in tris EDTA buffer for 5 min at 37’, 
after which the spectrum between 240 mn and 300 mn 
of both mixtures was recorded. The peak of ultraviolet 
absorption (263.5 nm) was similar in both cases; it 
appeared, therefore, that Mg2’ did not directly inter- 
act with 689, at least in such a way that would lead to 
alteration of its absorbancy characteristics. 
Preliminary experiments were also carried out with 
an enzyme fraction of higher specific activity obtained 
from C. cylindrosporum. Preincubation of the enzyme 
with 1 .O mM and 3.0 mM 689 for 3 min resulted in 
45% and 70% inhibition, respectively. 
CONCENTRATION OF 689 (mM) 
Fig. 2. The effect of preincubating Mg2+ with the enzyme 
fraction upon the subsequent inhibition by 689. The enzyme 
was incubated with Mg2+ for 15 min at 37’, after which 689 
was added for an additional 5 min of incubation. The reaction 
mixture (see Materials and methods) was added and the entire 
mixture incubated for an additional 20 mm. Concentration of 
Mg2+ preincubated with the enzyme: None, e---o ; 
6.15 mM , o--o; 12.3 mM C-A. 
4. Discussion 
It was concluded from these experiments that the 
6-halo, 8-aza, and 9cyclopentyl components of 689 
are all necessary to achieve full activity as an inhibitor 
of both RNA polymerase and formyltetrahydrofolate 
synthetase. It may be that the presence of the three 
groups in their respective positions in the purine ring 
is necessary to achieve a proper fit or attachment to a 
“receptor” site on the enzyme molecule and that the 
site of attack in both enzymes is similar. It has been 
suggested previously [2,6] that the halogen atom in 
position 6 of the purine nucleus could make 689 an 
“alkylating agent” and that the drug inhibits enzyme 
activity by being directed into an active site of the en- 
zyme as a result of its “nucleoside” structure and then 
irreversibly binding to it. 
The data from our experiments suggest hat 689- 
type analogs may have a differential sensitivity toward 
RNA polymerase from different organisms, a finding 
similar to that observed with the rifamycin group of 
antibiotics which also inhibit RNA polymerase activ- 
ity by interaction with the enzyme rather than the 
DNA template [7,8,9]. It would seem that this series 
of analogs might prove to be very useful tools for 
examining the functions of the various RNA polymer- 
ase subunits which have recently been described [lo]. 
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The N1O-formyl tetrahydrofolate (FH4) formed by 
formyltetrahydrofolate synthetase is subsequently con- 
verted to M, NlO-methenyl F& and then to I@, Nlo- 
methylene FHq. The latter coenzyme, also formed 
from the reaction between serine and tetrahydrofolic 
acid in the presence of L-serine hydroxymethyltrans- 
ferase, is employed as the one-carbon donor in the 
synthesis of thymidylic acid [ 1 l] . It is conceivable 
that 689 inhibits the formation of thymidylate by in- 
hibiting the formation of the necessary coenzymes. 
Since N1O-formyl FH4 is only one of the possible co- 
enzymes which can subsequently be used for thymi- 
dylate synthesis, the effect of 689 upon formation of 
@, N’O-methylene Fb in the L-serine hydroxymethyl- 
transferase reaction should be explored. 
The protective effect by Mg2’ upon enzyme activity 
may be due to binding of the cation to the enzyme and 
altering its conformation so that 689 may no longer 
attach to, or exert its effect upon, the enzyme. It is 
of interest that those divalent cations which cannot 
replace Mg2’ as the necessary metal for enzyme acti- 
vity, namely Ni2+ or Co2+ [12], were a lso capable of 
protecting the enzyme from 689. An extension of 
these studies may give further insight into the nature 
of the binding site attacked by 689 and its relationship 
to enzymatic function. 
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